IP Library › Patent Application 13587503
Patent Application
App. No. 13/587,503

THERAPEUTIC REGIMENS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/587,503
Abstract

The invention features pharmaceutical compositions and dosing regimens for the treatment of immunoinflammatory disorders.

Claims (20)

1 . A method for treating an immunoinflammatory disorder in a subject in need thereof, said method comprising:

i) administering to said subject a first dose of corticosteroid at time T 0 ; and

ii) administering to said subject a second dose of corticosteroid 3 to 8 hours after time T 0 ,

wherein the ratio of said first dose to said second dose is 1.5-2.5:1.

2 . The method of claim 1 , wherein the ratio of said first dose to said second dose is 2:1.

3 . The method of claim 1 , wherein said first dose is administered in a unit dosage formulation comprising from 1.4 to 2.3 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid, and said second dose is administered in a unit dosage formulation comprising from 0.70 to 1.20 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid.

4 . The method of claim 3 , wherein said first dose is administered in a unit dosage formulation comprising 1.8 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid, and said second dose is administered in a unit dosage formulation comprising 0.9 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid.

5 . The method of claim 1 , wherein said corticosteroid is selected from prednisolone, prednisone, budesonide, methylprednisolone, fluticasone, betamethasone, and deflazacort.

6 . The method of claim 1 , wherein said first dose is administered to said subject upon waking.

7 . The method of claim 1 , wherein said second dose is administered to said subject 4 to 6 hours after time T 0 .

8 . The method of claim 1 , wherein said corticosteroid is formulated for immediate release.

9 . The method of claim 1 , further comprising administering to said subject dipyridamole in unit dosage form.

10 . The method of claim 9 , wherein said unit dosage form comprises from 40 to 200 mg of dipyridamole.

11 . The method of claim 9 , wherein said dipyridamole is formulated for immediate release.

12 . A pharmaceutical composition in unit dosage form comprising (i) 1.4 to 2.3 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid; and (ii) 40 to 200 mg of dipyridamole.

13 . The pharmaceutical composition of claim 12 , wherein each of said corticosteroid and said dipyridamole is formulated for immediate release.

14 . The pharmaceutical composition of claim 12 , wherein said dipyridamole is formulated as a homogenous bead.

15 . A pharmaceutical composition in unit dosage form comprising (i) 0.70 to 1.20 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid; and (ii) 40 to 200 mg of dipyridamole.

16 . The pharmaceutical composition of claim 15 , wherein each of said corticosteroid and said dipyridamole is formulated for immediate release.

17 . The pharmaceutical composition of claim 15 , wherein said dipyridamole is formulated as a homogenous bead.